Clinical Trial

Study of GS-0151 in Participants With Rheumatoid Arthritis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.
Protocol Amendment History 1 change
notable Trial sites expanded: 32 -> 35 locations 2026-06-10
Trial Details
NCT Number NCT06902519
Lead Sponsor Gilead Sciences
Conditions Rheumatoid Arthritis
Enrollment 75 participants
Start Date 2025-05-14
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-09